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Abstract
Background: Epithelial defensins including human β-defensins (hBDs) and α-defensins (HDs) are
antimicrobial peptides that play important roles in the mucosal defense system. However, the role
of defensins in papillomavirus induced epithelial lesions is unknown.
Results:  Papilloma tissues were prospectively collected from 15 patients with recurrent
respiratory papillomatosis (RRP) and analyzed for defensins and chemokine IL-8 expression by
quantitative, reverse-transcriptase polymerase chain reaction (RT-PCR) assays. HBD-1, -2 and -3
mRNAs were detectable in papilloma samples from all RRP patients and the levels were higher than
in normal oral mucosal tissues from healthy individuals. Immunohistochemical analysis showed that
both hBD-1 and 2 were localized in the upper epithelial layers of papilloma tissues. Expression of
hBD-2 and hBD-3 appeared to be correlated as indicated by scatter plot analysis (r = 0.837, p <
0.01) suggesting that they were co-inducible in papillomavirus induced lesions. Unlike hBDs, only
low levels of HD5 and HD6 were detectable in papillomas and in oral mucosa.
Conclusion: Human β-defensins are upregulated in respiratory papillomas. This novel finding
suggests that hBDs might contribute to innate and adaptive immune responses targeted against
papillomavirus-induced epithelial lesions.
Background
Recurrent respiratory papillomatosis (RRP) is a disease
associated with human papillomavirus (HPV) infection of
the upper respiratory tract [1,2]. The condition is charac-
terized by abnormal proliferation of epithelial keratinoc-
ytes leading to papilloma formation, most commonly in
the larynx. The disease is often diagnosed during child-
hood and some patients have recurrent lesions through-
out adulthood. RRP is associated with significant
morbidity and can be life- threatening because of airway
obstruction. Current medical treatments are unsatisfac-
tory and repeated surgeries are required to relieve symp-
toms [3].
The pathogenesis of respiratory papilloma is poorly
understood. Although RRP is a relatively rare disease, HPV
infection is not uncommon in normal oral mucosa [4]. It
is thought that host factors such as immunodeficiency
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may predispose susceptible individuals to reactivation of
HPV infection [5,6]. Hence, both cell-mediated and
humoral immune mechanisms have been widely investi-
gated for their roles in HPV infection and disease [7,8]. In
contrast, much less is known about the role of innate
immunity in HPV infection, even though HPV disease is
characterized by localized viral replication and lesion for-
mation in the mucosal or cutaneous epithelial cells [8,9].
Since papillomaviruses complete their replication cycle in
terminally differentiated cells and release progeny virions
through desquamation of the epithelial surface, there is
relatively little exposure of viral antigens to the mecha-
nisms of immune surveillance. Therefore, infection with
HPV tends to be more persistent than with other
microbes. However, the vast majority of HPV infections in
immune competent hosts are eventually resolved, as evi-
denced by the high rate of remission of primary genital
HPV infection. This suggests that most infected hosts are
capable of mounting an effective immune response
against HPV infections.
Recent understanding of innate immunity indicates that
in addition to providing a first-line of defense against
invading organisms, innate immune mechanisms also
trigger the adaptive immune response [9]. Some impor-
tant components of innate mucosal immunity are α and β
defensins, which are cysteine-rich, cationic peptides that
display broad-spectrum antimicrobial activity. Although
α-defensins (HD1, -2, -3) are predominantly found in leu-
kocytes, HD5 and HD6 are expressed in intestinal and
genital tract epithelia [9]. Human β-defensins (hBDs)
including hBD-1, hBD-2, and hBD-3 are widely expressed
in epithelial cells [9,10]. These are detectable in most cuta-
neous and mucosal sites including the normal airway and
oral epithelium and are believed to be key mediators of
innate mucosal defense system [11-15]. For example,
both constitutively expressed hBD-1 and induced hBD-2
and hBD-3 have been shown to be microbicidal to a vari-
ety of bacterial and fungal pathogens [16,17], and more
recently, shown to inactivate both enveloped and non-
enveloped viruses including human immunodeficiency
virus type 1 (HIV-1) and adenovirus [18,19]. In addition
to their antimicrobial activity, hBD-2 also links innate and
adaptive immunity by attracting memory T cells and
recruiting immature dendritic cells through chemokine
receptor CCR6 [20].
Due to their location and role in antigen presentation,
epithelial dendritic or Langerhans cells are believed to be
essential for the initiation of adaptive immune response
against HPV infection [21]. Dendritic cells have been
shown to interact with HPV virions and virus-like-parti-
cles (VLP) and thus play a role in inducing protective
immunity against primary HPV infection [22-24]. Hence,
the demonstrated role of dendritic cells in HPV immunity
together with the influence of hBDs on their recruitment
makes it important to investigate the role of hBDs in pap-
illomavirus infections. We hypothesized that as with
other infections, expression of hBDs might be elevated in
HPV infected tissue and that hBDs might facilitate host
defense against papillomavirus infection.
We therefore investigated the expression of epithelial
associated defensins (hBD-1, hBD-2, hBD-3, HD5 and
HD6) in papilloma specimens obtained from RRP
patients and in normal oral mucosa. Since interleukin-8
(IL-8) or CXC-chemokine ligand 8 (CXCL8) is produced
by epithelial cells in response to infection or inflamma-
tory stimulation [25], we also investigated IL-8 expression
in these patients in order to determine if IL-8 is upregu-
lated in papillomas and whether defensin expression is
associated with IL-8 expression. We also attempted to
relate IL-8 and defensin expression to patient characteris-
tics including HPV genotype and disease severity.
Results
RRP patient demographics
The study population consisted of 15 patients with recur-
rent disease from both urban and rural areas in the state
of Mississippi. Demographics including racial back-
ground, age, sex and disease severity are shown in Table 1.
These patients were divided into a juvenile group (age
range 3–12 years), and an adult group (age range of 24 to
70 years). The diagnosis of RRP was determined by rou-
tine histopathology and clinical criteria with the disease
severity categorized as mild or severe (Table 1). HPV
detection and typing were performed for each patient so
that we could analyze the effect of infection with specific
Table 1: Patient demographics and HPV types
Patient No. Sex Age Race Disease state HPV type
Juvenile
1 Female 10 AA Severe 11
2F e m a l e 3 A A S e v e r e 1 1
3 Female 5 C Severe 6,11
4 Female 6 C Severe 6,11
5F e m a l e 3 A A S e v e r e 1 1
6M a l e 5 A A S e v e r e 6 , 1 1
7 Female 12 AA Mild 11
8 Female 10 AA Severe 6,11
9M a l e 8 A A S e v e r e 1 1
Adult
10 Male 57 C Severe 6,11
11 Female 35 AA Mild 11
12 Male 32 AA Mild 11
13 Female 24 C Mild 6
14 Male 70 C Mild 6
15 Male 45 C Mild 11
NOTE. AA, African American. C: CaucasianVirology Journal 2006, 3:75 http://www.virologyj.com/content/3/1/75
Page 3 of 8
(page number not for citation purposes)
HPV type on the expression of IL-8 and defensins. By
using a reverse line blot assay that could identify 37 HPV
genotypes, we found that all patients were positive for
HPV-6 or 11. It is interesting to note that all 9 patients in
the juvenile group were infected with HPV-11 and 4 of the
patients demonstrated co-infection with HPV-6. In the
adult group, only 1 of 6 patients showed co-infection with
HPV-6 and 11; the rest were either infected with HPV-11
or HPV-6 (Table 1).
Expression of hBD-1, hBD-2, hBD-3, HD5 and HD6 mRNA 
in papilloma tissues
Defensin expression was determined in freshly-obtained
papilloma specimens from 15 patients undergoing surgi-
cal treatment. hBD-1 and -2 were readily detected in all
papilloma tissue samples by RT-PCR analysis (Figure 1).
hBD-3 expression was weaker but still detectable in papil-
loma samples from all RRP patients. In similar experi-
ments, hBD-1, hBD-2 and hBD-3 were also detectable in
all ten samples of normal oral mucosa (Figure 1). The
expression of hBDs was quantified by real-time PCR and
hBD expression relative to normal oral mucosa is shown
in Figure 2. Expression of hBD-2 was highly upregulated
as evident by >1000-fold higher relative transcript levels.
Although hBD-3 was clearly expressed in papilloma tis-
sues, its level was much lower than either hBD-1 or hBD-
2 (Figure 2). Unlike the hBDs, HD5 and HD6 were not
consistently detectable at 35 cycles of PCR amplification
but were measurable at 40 cycles of amplification as per-
formed for real-time PCR (Figure 2).
Immunolocalization of hBD-1 and hBD-2 in papilloma 
tissue sections
To determine defensin protein expression, frozen sections
of respiratory papilloma tissues were subjected to immu-
nohistochemical staining with polyclonal rabbit antise-
rum for hBD-1 and goat antiserum for hBD-2.
Fluorescence microscopy showed strong immunostaining
of hBD-1 and hBD-2 in the upper epithelial layers includ-
ing the stratum granulosum and stratum spinosum (Fig-
ure 3). Unlike hBD-1, hBD-2 staining was more granular
and was strongly perinuclear (Figure 3A). Some epithelial
cells were stained for both hBD-1 and hBD-2, but hBD-2
staining appeared to be more widespread, especially in
spinous layers. Staining appeared to be specific for hBDs
since tissue sections exposed to serum preparations
derived from preimmune or unrelated immunogens
showed no reactivity (data not shown).
Correlation of mRNA expression among hBDs and IL-8 in 
papilloma tissues
IL-8 mRNA was expressed at low levels in normal mucosa
in healthy individuals but was modestly upregulated in
papilloma samples from RRP patients (Figure 2). As
expected of the inducible hBDs, hBD-2 expression was
highly correlated with hBD-3 as shown by scatter plot
RT-PCR analysis of hBD-1, hBD-2 and hBD-3 mRNA expression in RRP papilloma samples from 15 different individuals ((Left  Panel, Lanes 1–15) and normal oral mucosa tissue from 10 different individuals (Right Panel, Lanes 1–10) Figure 1
RT-PCR analysis of hBD-1, hBD-2 and hBD-3 mRNA expression in RRP papilloma samples from 15 different individuals ((Left 
Panel, Lanes 1–15) and normal oral mucosa tissue from 10 different individuals (Right Panel, Lanes 1–10). A housekeeping gene, 
β-actin (a), was detected as a 450 bp PCR product; hBD-1 (b), hBD-2 (c) and hBD-3 (d) expressions were detected as 108, 172 
and 98 bp PCR products, respectively. Samples were separated by 2% agarose gel electrophoresis and stained with ethidium 
bromide. 100 bp-ladder molecular-weight markers are presented on the left of the panel. Negative controls including amplifica-
tion without reverse transcriptase or with cDNA sample replaced by DNase, RNase – free, distilled water were performed in 
each experiment but are not shown due to limited gel space.Virology Journal 2006, 3:75 http://www.virologyj.com/content/3/1/75
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analysis (r = 0.837, p < 0.001). In our small study popula-
tion, we did not identify a correlation between hBD
expression and patient characteristics such as age, gender
and racial background. Expression of hBDs also appeared
not to correlate with infection with specific HPV types or
lesion severity. However, there was a trend that patients
with "severe" disease progression were more likely to dis-
play higher levels of IL-8 expression compared to "mild"
progression disease group (r = 0.537, p = 0.039).
Discussion
This report is the first to identify upregulated expression of
epithelial defensins (hBD-1, -2 and -3) in papillomavirus
associated lesions. RRP is a rare disease and therefore our
study population is relatively small. However, our results
clearly demonstrate the expression of epithelial defensin
in 100% of patient-derived papilloma tissue samples. The
modest but consistent upregulation of hBD-1 in papillo-
mas is unusual because hBD-1 expression is predomi-
nantly constitutive in most tissues. However, upregulated
expression of hBD-1 has been reported in monocytes
exposed to interferon-γ, bacteria or endotoxin [9], and in
human uterine epithelial cells exposed to poly (I:C), an
agonist for Toll-Like-Receptor 3 [26]. Our findings suggest
that, as with other microbial pathogens, infection with
papillomavirus is associated with high levels of epithelial
defensins even though HPV induced lesions are not
thought to elicit significant levels of tissue inflammation.
Although our study was performed on laryngeal papillo-
mas, hBD expression is likely upregulated in other papil-
lomavirus-induced lesions including both cutaneous and
mucosal genital warts since these lesions share very simi-
lar pathology. Several defensins, including hBD-1, hBD-2
and HD5, are known to be expressed in epithelial cells of
the urogenital tract [9]. Therefore, it is likely that these epi-
thelial defensins may also play a role in genital HPV infec-
tion. However, HD5 and HD6 are not associated with RRP
since these are only minimally expressed in respiratory
papilloma tissues. Others have reported that HD5 is pri-
marily expressed in intestinal paneth cells and the female
genital tract [9], but appears to be absent in airway epithe-
lia [27].
Recently, it has been reported that some members of the
defensin family of peptides play important roles in host
defense against certain viral infections such as the human
immunodeficiency virus (HIV-1), influenza and herpesvi-
ruses [18,28-31]. In addition to directly inactivating vir-
ion infectivity, defensins have been reported to block HIV-
1 viral replication in CD4+ cells by the inhibition of PKC
signaling [30]. In contrast, very little is known about the
potential role of defensins in HPV infection. Nevertheless,
several α-defensins (but apparently not the epithelial β-
defensins) have recently been shown to inhibit the initial
stages of HPV replication in a pseudovirus assay system
[32]. However, unlike HD5 that is expressed in the genital
tract, leukocyte associated α-defensins are much less likely
to be involved in HPV infection because of the limited cel-
lular infiltration in HPV lesions. In our study, hBDs
appeared to be ineffective at limiting viral disease progres-
sion since papillomas persisted despite the high level
expression of hBDs. Although we have not studied the
time course of hBDs upregulation in relation to infection,
it is tempting to speculate that hBDs might serve more as
signaling molecules that facilitate the generation of adap-
tive immune responses against a virus infection that elicits
little inflammatory events.
Conclusion
We demonstrated that beta-defensins were upregulated in
respiratory papillomas. The presence of inducible
defensins suggests that defensins might contribute to
innate and adaptive immune responses targeted against
papillomavirus infection. This observation is relevant to
vaccine development and could provide a rationale for
the development of defensin-based therapy for HPV using
exogenous defensin preparations or by enhancing the pro-
duction of defensins in target epithelial surfaces.
Methods
Patient population and specimen collection
The study protocol and all tissue procurement procedures
were reviewed and approved by the University of Missis-
sippi Medical Center Institutional Review Board oversee-
ing research on human subjects. Fifteen patients
undergoing surgical treatment for RRP at a tertiary care
hBD-1, hBD-2, hBD-3, HD5, HD6 and IL-8 mRNA expres- sions were analyzed by real-time RT-PCR Figure 2
hBD-1, hBD-2, hBD-3, HD5, HD6 and IL-8 mRNA expres-
sions were analyzed by real-time RT-PCR. Bars represent 
defensins expression normalized to β-actin and relative to 
normal mucosa using the 2-∆∆CT analysis as described in 
Materials and Methods. Error bars represent the standard 
error of the mean of triplicate analysis.
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center between January 2004 and January 2005 were
included in the study. Written, informed consent specify-
ing the use of remaining tissue was obtained from each
patient or legal guardian prior to collection. For control
experiments, samples of oral mucosa were collected from
ten individuals undergoing tonsillectomy due to tonsillar
hypertrophy. These patients had no symptoms of acute,
non-HPV upper-respiratory infection such as dysphagia,
sore throat, elevated body temperature, signs of inflam-
mation or plugs in the surface of the palatine tonsil. At the
time of surgery, they were not under drug treatment and
had no history of recurrent tonsillitis or allergy. Based on
the findings at the time of surgery, RRP patients were diag-
nosed as mild or severe disease. We defined "Mild" as dis-
ease confined to one surface of the larynx or recurrence
less than every six months. "Severe" includes patients with
lesions in any part of the larynx that may completely fills
the glottic airway or spreads outside of larynx and with
recurrence between one to six months.
Histology and immunohistochemistry
Tissue specimens were fixed in 10% buffered formalin
and processed for routine histological analysis. Frozen
sections were cut at 6 µM thickness from tissue samples
that were embedded in OCT-type freezing compound and
snap-frozen in liquid nitrogen. For immunostaining, rab-
bit polyclonal antiserum specific for hBD-1 and goat anti-
body specific for hBD-2 were obtained from Santa Cruz
Immunostaining of a representative frozen section of respiratory papilloma with antibody preparations to hBD-1 or hBD-2 Figure 3
Immunostaining of a representative frozen section of respiratory papilloma with antibody preparations to hBD-1 or hBD-2. 
Defensins were detectable as strong perinuclear staining of hBD-2 (A) and cytoplasmic immunostaining of hBD-1 (B) in all pap-
illoma sections. Tissue section was counterstained with DAPI (C), and a merged picture was shown in (D). Arrows indicate 
areas of negative staining for hBD-1 and hBD-2 immunostaining. Tissue sections exposed to antibody preparations derived 
from preimmune or unrelated immunogens showed no reactivity (data not shown).Virology Journal 2006, 3:75 http://www.virologyj.com/content/3/1/75
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Biotechnology, Inc. (Santa Cruz, CA). For double labe-
ling, FITC-labeled, donkey anti-goat and Texas red-
labeled, goat anti-rabbit antibodies were used. Also,
mounting medium (Vector Laboratories, Burlingame,
California) with DAPI was used for counterstaining.
DNA isolation and HPV typing
Total DNA was extracted using the Gentra Systems Pure-
gene DNA Purification Kit (Minneapolis, Minn). Speci-
mens were tested for the presence of HPV using improved
PGMY 09/11 L1 consensus primer systems (a set of 5
upstream oligonucleotides comprising the PGMY 11
primer pool and a set of 13 downstream oligonucleotides
comprising PGMY 09 primer pool) which amplify a 450
bp fragment of the L1 open-reading frame of a broad spec-
trum of HPV genotypes [33]. Amplifications were per-
formed using the following conditions: 95°C for 10 mins
and 40 cycles of denaturation at 95°C for 1 min, anneal-
ing at 55°C for 1 min, and extension at 72°C for 1 min,
then followed by final extension at 72°C for 5 min and a
hold step at 4°C. To assess tissue integrity, human β-
globin gene was co-amplified along with the HPV consen-
sus primers. The PCR products were separated by electro-
phoresis on 2% agarose gels and visualized by ethidium
bromide staining. The HPV genotypes in PCR products
were determined using Roche HPV Consensus PCR/Line
Blot Genotyping [34] reagents according to manufac-
turer's protocol.
Total RNA isolation
Tissue samples for RNA extraction were collected and
stored in RNAlater buffer (Ambion) and total RNA was
extracted using TRIzol Reagent (Invitrogen) according to
manufacturer's protocol. The RNA preparation was dis-
solved in 50–100 µl RNase free water depending on the
size of pellet. Residual DNA was removed from RNA prep-
arations by digestion with DNase Treatment and Removal
Reagents (DNA-Free, Ambion). The concentration and
purity of RNA samples were determined spectrophoto-
metrically by measuring absorbance at 260 and 280 nm
using NanoDrop 1000 A Spectrophotometer.
RT-PCR
Two µg of total RNA was reverse transcribed in a solution
of 20 µl containing 50 ng random hexamer primers, 1 mM
dNTP mix, 2 µl 10 × RT-buffer, 5 mM MgCl2, 10 mM DTT,
40 U RNaseOUT, and 200 U SuperScript III (Invitrogen)
reverse transcriptase at 25°C for 10 min, 50°C for 50 min
and the reaction was terminated at 85°C for 5 min. Con-
trol reactions were set up lacking reverse transcriptase to
assess the level of contaminating genomic DNA. RNA
template was removed from the cDNA: RNA hybrid by
incubation with RNase H. The synthesized cDNA was
then amplified by PCR using specific sense and antisense
primers for the genes of interest along with a housekeep-
ing gene, β-actin, as control. Primers (Invitrogen) used
were as follows: 
hBD-1 sense 5'-CCTTCTGCTGTTTACTCTCTGC-3', 
antisense  5'-CCACTGCTGACGCAATTGTAATG-3'; 
hBD-2 sense 5'-ATCAGCCATGAGGGTCTTGT-3', 
antisense 5'-GAGACCACAGGTGCCAATTT-3'; 
hBD-3 sense 5'-CTTCTGTTTGCTTTGCTCTTCC-3', 
antisense 5'-CCTCTGACTCTGCAATAATA-3'; 
HD5 sense 5'-ACCTCAGGTTCTCAGGCAAGAGC-3', 
antisense 5'-GACACAAGGTACACAGAGTAAAATGT-3'; 
HD6 sense 5'-GCTTTGGGCTCAACAAGGGCTTTC-3',
antisense 5'-GACACACGACAGTTTCCTTCTAGGTCATA-
3'; IL-8 sense TTGGCAGCCTTCCTGATTTC-3', 
antisense 5'-AACTTCTCCACAACCCTCTG-3', and β-actin
sense 5'-TGTGCCCATCTACGAGGG GTATGC-3', 
antisense 5'-GGTACATGGTGGTGCCGCCAGACA-3').
Thermal cycling conditions consisted of an initial dena-
turing step (96°C, 5 min) followed by 35 cycles of dena-
turing (94°C, 30 s), annealing (30 s at temperatures for
specific primers as stated below), and extending (72°C,
30 s), followed by 3 min at 72°C for elongation. The
annealing temperature for hBD-1, hBD-2, hBD-3, HD5,
HD6, IL-8 and β-actin were 52°C, 52°C, 43°C, 53°C,
61°C, 49°C, and 64°C, respectively. RT-PCR products
were subsequently verified by electrophoresis on 2% aga-
rose gels containing 0.5 µg/ml ethidium bromide and vis-
ualized under UV transillumination. Molecular weights of
the products were determined using a DNA molecular-
weight marker (Perfect DNA 100 bp Ladder, Novagen,
Madison WI). Under these conditions, PCR products of
108 bp (hBD-1), 172 bp (hBD-2), 98 bp (hBD-3), 251 bp
(IL-8) and 450 bp (β-actin) were generated. All amplifica-
tion products detected in this study were sequenced to
confirm the identity of the defensin of interest.
Real-time quantitative PCR analysis
Real-time quantitation of defensin mRNA was performed
using SYBR-green PCR assay and an iCycler PCR machine
(Bio-Rad Laboratories, Hercules, CA). 0.5 µl cDNA was
amplified in a 25 µl reaction solution containing 22.5 µl
of iQ SYBR Green supermix (Bio-Rad) and 1 µl of each
primer (as described above). Each sample was loaded in
triplicate and run at 40 cycles under the conditions stated
above. After each run, melting curves were generated to
confirm amplification of specific transcripts. To deter-
mine relative levels of gene expression, the comparative
threshold cycle (CT) method was employed [35]. CT was
defined as the cycle number at which reporter fluores-
cence reached 10 times the standard deviation of the base-
line fluorescence. For each sample, the mean CT value
obtained for β-actin was subtracted from the mean CT
value for the gene of interest to derive a ∆CT value. The ∆CT
of test samples was then subtracted from ∆CT of the con-
trol sample to generate a ∆∆CT. The mean of these ∆∆CT
measurements was then used to calculate target geneVirology Journal 2006, 3:75 http://www.virologyj.com/content/3/1/75
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expression normalized to β-actin and relative to the con-
trol as: Relative Expression = 2-∆∆CT.
Statistics
The relationships between mRNA expression of hBD-1,
hBD-2, hBD-3 and IL-8 in RRP subjects (n = 15) were
studied using the scatter plot method. Statistical compari-
sons were computed using Spearman's nonparametric
correlations for each bivariate pair.
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